Bajaj Healthcare Ltd, on 23 September, announced that they have entered into a development and supply agreement for an API with a European entity. 

Initially, the Active Pharmaceutical Ingredient (API) will be supplied in small quantities after development and will be used by the European partner to carry out clinical trials for an alternative indication. 

The supply of these APIs will be based on the outcome of these trials and will be done from Bajaj Healthcare’s FDA-approved manufacturing facility in Vadodara, Gujarat. 

The company, in its filing, said, “The trust reposed in our company by the EU partner for sourcing clinical trial quantities is a testimony of the company’s development and manufacturing capabilities along with the Good Manufacturing Practices compliance at the company’s manufacturing units.”

Earlier, the company signed definitive CMO agreements with customers in the European Union and the UK for the supply of 15 APIs. 

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!